- Home
- TRUG vs SNGX Comparison
TRUG vs SNGX Comparison
Compare TRUG & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- SNGX
- Stock Information
- Founded
- TRUG 1983
- SNGX 1987
- Country
- TRUG United States
- SNGX United States
- Employees
- TRUG N/A
- SNGX N/A
- Industry
- TRUG
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- SNGX Health Care
- Exchange
- TRUG NYSE
- SNGX Nasdaq
- Market Cap
- TRUG 7.0M
- SNGX 6.5M
- IPO Year
- TRUG N/A
- SNGX 1987
- Fundamental
- Price
- TRUG $5.78
- SNGX $1.32
- Analyst Decision
- TRUG Strong Buy
- SNGX Strong Buy
- Analyst Count
- TRUG 1
- SNGX 1
- Target Price
- TRUG $100.00
- SNGX $6.00
- AVG Volume (30 Days)
- TRUG 84.7K
- SNGX 2.7M
- Earning Date
- TRUG 08-13-2025
- SNGX 08-08-2025
- Dividend Yield
- TRUG N/A
- SNGX N/A
- EPS Growth
- TRUG N/A
- SNGX N/A
- EPS
- TRUG N/A
- SNGX N/A
- Revenue
- TRUG $22,236,072.00
- SNGX $2,342.00
- Revenue This Year
- TRUG $9.66
- SNGX N/A
- Revenue Next Year
- TRUG $48.94
- SNGX N/A
- P/E Ratio
- TRUG N/A
- SNGX N/A
- Revenue Growth
- TRUG 8.40
- SNGX N/A
- 52 Week Low
- TRUG $5.00
- SNGX $1.09
- 52 Week High
- TRUG $73.50
- SNGX $5.40
- Technical
- Relative Strength Index (RSI)
- TRUG 42.37
- SNGX 41.75
- Support Level
- TRUG $5.00
- SNGX $1.34
- Resistance Level
- TRUG $6.80
- SNGX $1.46
- Average True Range (ATR)
- TRUG 0.72
- SNGX 0.11
- MACD
- TRUG 0.27
- SNGX 0.03
- Stochastic Oscillator
- TRUG 22.14
- SNGX 62.16
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).